Abstract:Dear Sir, We read with great interest the article by Ikeura et al.1 assessing the efficacy of the prognostic factor score in the Japanese severity criteria for acute pancreatitis (AP). By analyzing 1159 patients with severe AP, they showed that the area under the curve (AUC) for the receiver-operating characteristic curve of the prognostic factor score for predicting AP-related mortality was 0.78, which was comparable to that for the well-known acute physiology and chronic health evaluation (APACHE) II score (AUC = 0.80). One weakness of their study is that mild AP cases were not included in the analysis due to the study design. In addition, severity assessment using the nine factors might be too complicated. In Japan, the Research Committee of Intractable Pancreatic Diseases, under the support of the Ministry of Health, Labor, and Welfare of Japan, has conducted nationwide epidemiological surveys of AP including both severe and mild cases every 4–5 years.2-4 We recently reported that four (base excess or shock, renal failure, systemic inflammatory response syndrome criteria and age) out of the nine prognostic factors were associated with AP-related death by multivariate analysis in the 2011 survey.5 Here, we validated the utility of the severity assessment system based on these four factors in 3682 AP cases collected for the 2003 (285 cases), 2007 (1146 cases), and 2011 (2251 cases) surveys. We performed receiver-operating characteristic curve analysis to evaluate the predictive accuracy of the prognostic factor scores for mortality. The AUC was 0.80 for the nine prognostic factors. If the cut-off point was set at score = 3 as adopted currently, the sensitivity was 0.47 with a specificity of 0.93. The AUC for predicting mortality was 0.78 for the four prognostic factors, suggesting the comparable utility of these four factors in the severity assessment. The sensitivity was 0.53 with a specificity of 0.92 if the cut-off point was set at score = 2. If we define the patients fulfilling at least two out of the four prognostic factors as severe, 342/3682 (9.3%) patients had severe AP. The mortality of severe AP cases was 17.3% (59/342), whereas that of mild AP cases was 1.6% (52/3340) (Figure 1 ). If we choose only two factors (renal failure and age) that showed a stronger association with AP-related mortality among the four factors,5 the AUC was decreased to 0.72. The sensitivity was 0.22 with a specificity of 0.98 if the cut-off point was set at score = 2. Mortality of the 3682 acute pancreatitis patients stratified by the four prognostic factor scores. Number of patients in each category is shown in the parentheses. Our results suggested that severity assessment using the four prognostic factors was equivalent to the current Japanese severity criteria employing nine factors. Accurate assessment of severity in patients with AP is still a challenge.6 Development of a more convenient and accurate severity assessment system would contribute to improving the outcomes of this intractable disease. None declared. This study was approved by the Ethics Committee of Tohoku University Graduate School of Medicine (article #: 2015-1-519). Supported by grants from the Smoking Research Foundation (to Atsushi Masamune). This study based on an anonymous questionnaire and does not require informed consent from patients.

Severity of Acute Pancreatitis in Patients with Inflammatory Bowel Disease in the Era of Biologics: A Propensity‐score‐matched Analysis Using a Nationwide Database in Japan

Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000

Treatment of Inflammatory Bowel Disease with Biologics in Japan: A Single-Center, Retrospective Pharmacoeconomic Study

Acute pancreatitis in children with inflammatory bowel disease: Risk factors, clinical course, and prognosis

Anti‐TNF and Immunosuppressive Combination Therapy is Preferential to Inducing Clinical Remission in Patients with Active Inflammatory Bowel Disease: A Systemic Review and Meta‐analysis

P1187 Persistence of Advanced Therapies in Patients with Inflammatory Bowel Disease: Retrospective cohort study using large healthcare claims database in Japan

P271 Impact of Biologics on Surgical Trends in Inflammatory Bowel Disease: Insights from a Lower-endemic Region

Acute Pancreatitis in Japan Comparison of Before and After Revision of the Clinical Guidelines

EFFICACY OF BIOLOGIC DRUGS IN SHORT-DURATION VERSUS LONG-DURATION INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND INDVIDUAL-PATIENT-DATA METANALYSIS OF RANDOMIZED CONTROLLED TRIALS

[Effects of Biologics on Psychological Status and Quality of Life in Patients with Inflammatory Bowel Disease: a Multicenter Study].

A descriptive study evaluating the circumstances of medical treatment for acute pancreatitis before publication of the new JPN guidelines based on the Japanese administrative database associated with the Diagnosis Procedure Combination system

Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials

The Efficacy and Safety of Biological and Immunosuppressive Combination Therapy Are Equal to Biological Monotherapy for Inflammatory Bowel Disease: A Systemic Review and Meta-Analysis

P1219 Changes in gut microbiota of patients with inflammatory bowel disease receiving biologic therapy

Current Use of Immunosuppressive Agents in Inflammatory Bowel Disease Patients in East China

Long‐term Prognosis and Clinical Practice for New‐onset Ulcerative Colitis in the Era of Biologics: A Japanese Retrospective Study

Efficacy of Biological Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: a Protocol for a Systematic Review and an Individual-Patient Level Meta-Analysis of Randomised Controlled Trials

Severity Assessment of Acute Pancreatitis Using Four Prognostic Factors – a Nationwide Multicenter Study of 3682 Cases in Japan

Clinical Features Focusing on Extraintestinal Manifestations in Japanese Patients with Inflammatory Bowel Diseases: Far East 1000

Inflammatory bowel disease complicating with pancreatic abnormalities: a single center analysis

Biological agents in the treatment of Crohn's disease: a propensity score-matched analysis from the prospective Persistence Australian National IBD Cohort (PANIC3) study